⚠ Capacity Bets Are Capital-Intensive and RiskyModerate threat

Scaling manufacturing to serve the surge means committing capital to capacity ahead of demand, and that is a genuine risk for a company whose demand rests on a possibly-temporary boom. Factories and capacity are expensive and take time to build, so Bloom must invest now, at the peak, on the assumption that the AI-power demand persists long enough to fill them. If that assumption proves wrong — if the AI-spending frenzy cools, the grid catches up faster than expected, or competition captures share — Bloom could be left with costly, underutilized manufacturing, and the operating leverage that turned rising volume into surging profits would work brutally in reverse, fixed costs crushing margins as revenue softens. Building for a peak that then recedes is the oldest trap in capital-intensive industries, and Bloom is exposed to it precisely now.

The capital intensity compounds Bloom's other financial vulnerabilities. Funding the capacity ramp draws on a balance sheet that, though improving with the newfound profits, is not a fortress, and on the external financing that Bloom depends on for growth — so a large capacity bet increases both the funding dependence and the downside if demand disappoints. Bloom has executed its production ramp impressively and, if the demand is as durable as the backlog suggests, the capacity will be well-used and could yield real cost advantages. But an investor should weigh the asymmetry: scaling capacity into the surge is necessary to capture the opportunity, yet it converts a demand risk into a fixed-cost risk, so that a cooling of the boom would hurt Bloom not only through lower revenue but through the stranded cost of capacity built for a demand level that did not last. The capital bet is the right one only if the surge — +166% revenue growth in its latest quarter¹ — endures, and its durability is exactly what is unproven.